Abstract：
UNASSIGNED: Hepatic cancer is a common cancer in clinical practice. Current drug therapies for this condition include targeted therapy, chemotherapy, and immunotherapy. Tumor lysis syndrome (TLS) is the most serious complication of oncology treatment. According to the literature, several cases reported TLS occurred with targeted therapies for hepatic cancer.
UNASSIGNED: Reporting odds ratio and information component were used to measure the disproportionate signals for TLS associated with targeted therapies, using data from the FDA\'s Adverse Event Reporting System (FAERS). A stepwise sensitivity analysis was conducted to test the robustness of signals. Time-to-onset analysis was used to describe the latency of TLS events associated with targeted therapies. The Bradford Hill criteria were used to perform a global assessment of the evidence.
UNASSIGNED: Sorafenib, lenvatinib, cabozantinib, and bevacizumab showed higher disproportionate signals for TLS than chemotherapy. The median number of days to TLS occurrence after drug therapy was 5.5, 6.5, and 6.5 days for sorafenib, lenvatinib, and bevacizumab, respectively.
UNASSIGNED: There is a significant association between tumor lysis syndrome and targeted therapies for hepatic carcinoma, with particularly strong signals for sorafenib and lenvatinib. Clinicians should be aware of the potential for tumor lysis syndrome in targeted therapies for hepatic carcinoma.
UNASSIGNED: Reporting odds ratio and information component were used to measure the disproportionate signals for TLS associated with targeted therapies, using data from the FDA\'s Adverse Event Reporting System (FAERS). A stepwise sensitivity analysis was conducted to test the robustness of signals. Time-to-onset analysis was used to describe the latency of TLS events associated with targeted therapies. The Bradford Hill criteria were used to perform a global assessment of the evidence.
UNASSIGNED: Sorafenib, lenvatinib, cabozantinib, and bevacizumab showed higher disproportionate signals for TLS than chemotherapy. The median number of days to TLS occurrence after drug therapy was 5.5, 6.5, and 6.5 days for sorafenib, lenvatinib, and bevacizumab, respectively.
UNASSIGNED: There is a significant association between tumor lysis syndrome and targeted therapies for hepatic carcinoma, with particularly strong signals for sorafenib and lenvatinib. Clinicians should be aware of the potential for tumor lysis syndrome in targeted therapies for hepatic carcinoma.
摘要：
■肝癌是临床实践中常见的癌症。目前针对这种情况的药物治疗包括靶向治疗，化疗,和免疫疗法。肿瘤溶解综合征（TLS）是肿瘤治疗中最严重的并发症。根据文献,一些病例报告TLS发生在肝癌的靶向治疗中.
■报告比值比和信息分量用于测量与靶向治疗相关的TLS的不成比例信号，使用FDA不良事件报告系统(FAERS)的数据。进行逐步灵敏度分析以测试信号的鲁棒性。使用发病时间分析来描述与靶向治疗相关的TLS事件的潜伏期。BradfordHill标准用于对证据进行全球评估。
■索拉非尼，lenvatinib,卡博替尼,贝伐单抗对TLS的不成比例信号高于化疗.索拉非尼在药物治疗后发生TLS的中位天数为5.5、6.5和6.5天，lenvatinib,分别是贝伐单抗。
■肿瘤溶解综合征与肝癌的靶向治疗之间存在显著关联，索拉非尼和乐伐替尼信号特别强烈。临床医生应该意识到肿瘤溶解综合征在肝癌靶向治疗中的潜力。
■报告比值比和信息分量用于测量与靶向治疗相关的TLS的不成比例信号，使用FDA不良事件报告系统(FAERS)的数据。进行逐步灵敏度分析以测试信号的鲁棒性。使用发病时间分析来描述与靶向治疗相关的TLS事件的潜伏期。BradfordHill标准用于对证据进行全球评估。
■索拉非尼，lenvatinib,卡博替尼,贝伐单抗对TLS的不成比例信号高于化疗.索拉非尼在药物治疗后发生TLS的中位天数为5.5、6.5和6.5天，lenvatinib,分别是贝伐单抗。
■肿瘤溶解综合征与肝癌的靶向治疗之间存在显著关联，索拉非尼和乐伐替尼信号特别强烈。临床医生应该意识到肿瘤溶解综合征在肝癌靶向治疗中的潜力。
